8-K: Alector Appoints Neil Berkley as Permanent CFO
Executive Appointment
Alector, Inc. has officially appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025, solidifying his interim role.
Summary
- Alector, Inc. announced the appointment of Neil Berkley as its Chief Financial Officer (CFO), effective December 10, 2025.
- Mr. Berkley had been serving as Interim Chief Financial Officer since June 2025.
- He will continue to serve in his role as Chief Business Officer (CBO), a position he has held since March 2024, and as the principal financial officer.
- There are no changes to Mr. Berkley's existing compensatory arrangements as a result of this appointment.
- The appointment was announced via a press release on December 12, 2025.
Sentiment
Score: 7
Explanation: The sentiment is positive due to the formalization of a key leadership role with an experienced executive who was already familiar with the company, ensuring continuity and strategic alignment. No negative aspects were disclosed.
Positives
- The appointment of Neil Berkley as CFO provides continuity and stability, as he has been serving as Interim CFO since June 2025 and CBO since March 2024.
- Mr. Berkley brings over two decades of experience in corporate strategy, finance, business development, and operations across various biotech and pharmaceutical companies.
- His dual role as CFO and CBO ensures a deep understanding of both the company's scientific drivers and financial strategy.
- Management expressed confidence in Mr. Berkley's leadership, judgment, strategic insight, and commitment to Alector's mission.
Future Outlook
Alector aims to advance its promising pipeline of therapies for neurodegenerative diseases, including Alzheimer's, Parkinson's, and frontotemporal dementia, and continue the development of its proprietary Alector Brain Carrier (ABC) platform to enhance therapeutic delivery and efficacy.
Management Comments
- Arnon Rosenthal, Ph.D., CEO of Alector, stated: "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission. His deep understanding of our science and business drivers—combined with his operational and financial acumen—makes him uniquely suited to assume the CFO role as we advance through an important period for the company."
- Neil Berkley commented: "I'm honored to serve Alector in this capacity. It is a privilege to work with such a talented team dedicated to advancing transformative therapies to patients with neurodegenerative diseases. I look forward to continuing to support the company's scientific and corporate priorities, including the advancement of our promising pipeline and the ongoing development of our ABC-enabled programs."
Industry Context
The appointment of a seasoned financial and business development executive like Neil Berkley is a common strategic move for clinical-stage biotechnology companies like Alector. Such companies often require strong leadership in finance and corporate strategy to navigate complex R&D funding, potential partnerships, and eventual commercialization efforts in the highly competitive neurodegeneration therapeutic space.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Neil Berkley (Interim) | Neil Berkley | December 10, 2025 | Formal appointment after serving as Interim CFO and CBO, recognizing his leadership and experience. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Appointment | The Board of Directors formally appointed Neil Berkley as Chief Financial Officer, solidifying his role after serving as Interim CFO. | December 10, 2025 | Enhances leadership stability and strategic direction by formalizing a critical executive position with an experienced individual already integrated into the company's operations and strategy. |
Stakeholder Impact
- Shareholders: The formal appointment of an experienced CFO who also serves as CBO may instill confidence in the company's financial management and strategic direction, potentially contributing to share price stability.
- Employees: Provides clarity and stability in the executive leadership team, which can positively impact morale and operational focus.
- Patients: The continued focus on advancing the pipeline and the ABC platform under stable leadership reinforces the company's commitment to developing therapies for neurodegenerative diseases.
Next Steps
- Continue advancing Alector's pipeline of therapies for neurodegenerative diseases.
- Further develop the Alector Brain Carrier (ABC) platform for enhanced therapeutic delivery.
Key Dates
| Date | Description |
|---|---|
| March 2024 | Neil Berkley began serving as Alector's Chief Business Officer (CBO). |
| June 2025 | Neil Berkley began serving as Alector's Interim Chief Financial Officer (CFO). |
| December 10, 2025 | Neil Berkley was officially appointed as Chief Financial Officer, effective on this date. |
| December 12, 2025 | Alector issued a press release announcing Neil Berkley's appointment as CFO and filed the Form 8-K. |
Keywords
Alector, biotechnology, neurodegeneration, CFO appointment, Chief Financial Officer, Chief Business Officer, executive leadership, corporate governance, ALEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.